Stoke Therapeutics logo
Stoke Therapeutics
STOK | NASDAQ
Chart Builder DCF Calculator
$26.63
-$0.05 (-0.19%)
At close: Nov 16, 2026, 4:00 PM ET
$26.63
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Stoke Therapeutics Company Profile

Company profile explained

Company Profile

Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.

Key Executives

Name Position
Ian F. Smith Chief Executive Officer & Director
Sara Den Besten Chief People Officer
Thomas Edward Leggett Chief Financial Officer
Adrian R. Krainer Co-Founder & Independent Director
Barry S. Ticho FACC Chief Medical Officer
Edward Kaye Advisor & Director
Isabel Aznarez Co-Founder & CTO
Jason Hoitt Chief Patient Officer
Jonathan Allan Corporate Secretary, Compliance Officer & General Counsel
Susan Willson Vice President of Corporate Communications
Thomas McCauley Chief Scientific Officer

Latest SEC Filings

Date Type Title
Oct 29, 2026 8-K Current Report
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Sep 30, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Sep 25, 2026 4 Filing
Sep 25, 2026 3 Filing
Sep 25, 2026 8-K Current Report
Sep 03, 2026 4 Filing
Aug 18, 2026 4 Filing
Aug 18, 2026 4 Filing
View All SEC Filings ➞
Stoke Therapeutics
Stoke Therapeutics logo
Country United States
IPO Date Jun 19, 2019
Industry Biotechnology
Sector Healthcare
Employees 170
CEO Ian F. Smith

Contact Details

45 Wiggins Avenue Bedford, Massachusetts 01730 United States

Stock Details

Ticker Symbol STOK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001623526
CUSIP Number 86150R107
ISIN Number US86150R1077
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.